Novocure appoints Dr. Nicolas Leupin as CMO; Pritesh Shah steps down as executive officer

NovoCure Ltd

Dr. Nicolas Leupin appointed CMO, overseeing medical affairs, safety, and clinical development.
Pritesh Shah resigns as executive officer; to serve as Senior Advisor to CEO through June 30, 2025.
Frank Leonard appointed EVP and President, Novocure Oncology; base salary $525,000, target bonus 60%.
Shah's salary drops from $500k to $120k after June 2024; equity grants continue vesting.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Pritesh Shah

Chief Growth Officer

NVCR · NovoCure Ltd

Effective: 2024-01-01
Filed: January 4, 2024, 6:59 PM ET

Effective January 1, 2024, Pritesh Shah, Chief Growth Officer of the Company, resigned his position as an executive officer of the Company and agreed to become a Senior Advisor to the Chief Executive Officer, a non-executive position.

Appointed

Frank Leonard

Executive Vice President and President, Novocure Oncology

NVCR · NovoCure Ltd

Effective: 2024-01-01
Filed: January 4, 2024, 6:59 PM ET

Effective January 1, 2024, the Company appointed Frank Leonard, Executive Vice President and President, Novocure Oncology.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Pritesh Shah resigned as Chief Growth Officer at NovoCure Ltd.

Action: resigned
Role: Chief Growth Officer

Exact text from the filing

Effective January 1, 2024, Pritesh Shah, Chief Growth Officer of the Company, resigned his position as an executive officer of the Company and agreed to become a Senior Advisor to the Chief Executive Officer, a non-executive position.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Frank Leonard was appointed as Executive Vice President and President, Novocure Oncology at NovoCure Ltd.

Action: appointed
Role: Executive Vice President and President, Novocure Oncology

Exact text from the filing

Effective January 1, 2024, the Company appointed Frank Leonard, Executive Vice President and President, Novocure Oncology.

View on SEC.gov

NovoCure Ltd filing history →

Source: SEC EDGAR

accession 0001645113-24-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.